Perrigo Company plc (NYSE:PRGO) Shares Sold by Yousif Capital Management LLC

Yousif Capital Management LLC trimmed its position in shares of Perrigo Company plc (NYSE:PRGO) by 3.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 45,061 shares of the company’s stock after selling 1,396 shares during the period. Yousif Capital Management LLC’s holdings in Perrigo were worth $1,159,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Franklin Resources Inc. acquired a new stake in Perrigo during the 3rd quarter worth approximately $3,717,000. Foundry Partners LLC acquired a new stake in shares of Perrigo in the third quarter valued at $7,111,000. Barclays PLC boosted its stake in shares of Perrigo by 44.8% in the 3rd quarter. Barclays PLC now owns 120,502 shares of the company’s stock valued at $3,160,000 after buying an additional 37,268 shares during the period. JPMorgan Chase & Co. raised its holdings in Perrigo by 65.1% in the third quarter. JPMorgan Chase & Co. now owns 541,000 shares of the company’s stock valued at $14,190,000 after acquiring an additional 213,221 shares in the last quarter. Finally, Citigroup Inc. lifted its stake in Perrigo by 94.1% in the third quarter. Citigroup Inc. now owns 151,520 shares of the company’s stock worth $3,974,000 after acquiring an additional 73,457 shares during the last quarter. 95.91% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Perrigo

In other news, Director Jeffrey B. Kindler sold 17,598 shares of Perrigo stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $28.27, for a total transaction of $497,495.46. Following the completion of the sale, the director now directly owns 5,409 shares in the company, valued at approximately $152,912.43. This trade represents a 76.49 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.70% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

PRGO has been the topic of a number of analyst reports. StockNews.com upgraded Perrigo from a “hold” rating to a “buy” rating in a research note on Monday. Argus downgraded Perrigo from a “buy” rating to a “hold” rating in a report on Tuesday, January 14th. Finally, Piper Sandler downgraded Perrigo from an “overweight” rating to a “neutral” rating and dropped their price target for the stock from $34.00 to $27.00 in a research note on Monday, January 6th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $35.00.

Perrigo Stock Performance

Shares of PRGO opened at $24.80 on Friday. The stock has a market capitalization of $3.38 billion, a P/E ratio of -21.19 and a beta of 0.54. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.77 and a current ratio of 2.56. Perrigo Company plc has a 1 year low of $23.14 and a 1 year high of $33.46. The company’s fifty day moving average is $25.32 and its two-hundred day moving average is $26.40.

Perrigo Company Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.